Anti-angiogenic potential of Gleditsia sinensis fruit extract.
Blood supply plays a crucial role in solid tumour development and leukaemogenesis. It has been suggested that blocking of angiogenesis could be possible in cancer therapy. We have demonstrated the antiproliferative activity of Gleditsia sinensis fruit extract (GSE) on various human solid tumour cancer cell lines as well as leukaemia cell lines and primary cultured leukaemia cells obtained from leukaemia patients. However, the antiangiogenic potential of GSE has not been demonstrated. Here we demonstrated that GSE could reduce vascular endothelial growth factor (VEGF) mRNA expression in dose- and time course-dependently in MDA-MB231 breast cancer and HepG2 hepatoblastoma cell lines as measured by reverse transcriptase polymerase chain reaction. Enzyme-linked immunosorbent assay further showed that GSE could reduce the VEGF secretion from various cancer cell lines including MDA-MB231, HepG2, HL-60 (acute promyelocytic leukaemia) and eleven primary cultured leukaemia cells obtained from acute myelogenous leukaemia patients. In vivo chick chorioallantoic membrane assay illustrated that GSE could reduce the angiogenic activity of basic fibroblast growth factor. Taken together, the information suggested that GSE could be potentially used as an angiogenic inhibitor in both solid tumour and leukaemia therapy.
Chow
Larry Ming Cheung
LM
Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China. bclchow@polyu.edu.hk
Chui
Chung Hin
CH
Tang
Johnny Cheuk On
JC
Lau
Fung Yi
FY
Yau
Mabel Yin Chun
MY
Cheng
Gregory Yin Ming
GY
Wong
Raymond Siu Ming
RS
Lai
Paul Bo San
PB
Leung
Thomas Wai Tong
TW
Teo
Ivy Tuang Ngo
IT
Cheung
Filly
F
Guo
Dean
D
Chan
Albert Sun Chi
AS
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000188:drug therapy*; D002642:Chick Embryo; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D016228:Endothelial Growth Factors / Q000235:genetics / Q000378:metabolism; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000187:drug effects; D005638:Fruit / Q000737:chemistry; D031501:Gleditsia / Q000737:chemistry*; D018922:HL-60 Cells / Q000187:drug effects; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy*; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy*; D008222:Lymphokines / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D010936:Plant Extracts; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2